Capital Gain

Johnson & Johnson’s single-dose COVID-19 vaccine is 66% effective, lagging rivals

Published: (Updated: ) in FINTECH, , , , , , , , , , , , , , , , , , by .

Johnson & Johnson’s single-dose COVID-19 vaccine is 66% effective, lagging rivals




Johnson & Johnson’s single-dose COVID-19 vaccine is 66% effective, lagging rivals | Fortune



Source link

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *